1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too

 
• By Joseph Haas

Emerging Company Profile: Calling itself the most advanced microbiome company focused on skin diseases, MatriSys has advanced a proprietary microbe to Phase IIa for atopic dermatitis. The biotech also is eyeing UV-induced cancer, rosacea, acne, psoriasis and bacterial skin infections.

Emerging Company Profile Regular column feature image Version 2

Often the first thing MatriSys Bioscience Inc.’s team needs to explain to potential investors is that microbiome therapy isn’t focused solely on gastrointestinal disorders, although that’s an easier task since the firm unveiled interim Phase IIa data for lead candidate MSB-01 in atopic dermatitis in February.

While MSB-01 – a topical preparation of a proprietary bacterial strain of the microbe Staphylococcus hominis A9 – completes the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.